Professor Colin Dayan
Projects as PI
1 of 10
- Accelerate the route to patient benefit of new interventions to preserve beta cell function in T1D - Study Plus (01/01/2023 - 28/02/2025)
- Albiglutide versus placebo in insulin-treated subjects with new-onset Type 1 Diabetes mellitus (22/01/2015 - 31/03/2020)
- A phase 1, randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of NGM217 in adults with autoimmune diabetes (11/04/2018 - 31/03/2020)
- Beta cell preservation via antigen-specific immunotherapy in type 1 diabetes: Enhanced epidermal antigen delivery systems (01/09/2012 - 31/05/2017)
- Clinical Trial (01/12/2015 - 31/03/2020)
Projects as Co-Investigator
1 of 4
- A new window into the immune response funding during Type 1 Diabetes (01/11/2017 - 31/05/2019)
- B cells in newly diagnosed type 1 diabetes (01/03/2012 - 31/07/2016)
- Bringing immunotherapy for type 1 diabetes into the clinic: New windows into the immune response (01/05/2018 - 30/04/2019)
- Cardiovascular disease research (01/11/2013 - 31/10/2016)
- Development of urinary microRNAs as biomarkers for diabetic kidney disease (01/04/2013 - 31/07/2018)
